TIE1 and neoplasm: Ang/Tie pathway has indeed become an interesting target for new drug development, as MEDI 3671 (a monoclonal antibody against Ang2), trebananib (fusion protein which hampers the binding of Ang1/2 to Tie 1⁄2) or CovX bodies have demonstrated the ability to inhibit tumor growth and decrease vascular density [144,145,146,147].